Reserpine

Revision as of 22:25, 4 July 2014 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search

Reserpine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Reserpine is a catecholamine-depleting sympatholytic that is FDA approved for the {{{indicationType}}} of mild essential hypertension. Common adverse reactions include abdominal pain, diarrhea, nausea, vomiting, xerostomia, dizziness, headache, lethargy, somnolence, vertigo, depression, and nasal congestion.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Reserpine in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Reserpine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Reserpine in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Reserpine in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Reserpine in pediatric patients.

Contraindications

  • Condition1

Warnings

  • Description


Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Reserpine in the drug label.

Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Reserpine in the drug label.

Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Reserpine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Reserpine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Reserpine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Reserpine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Reserpine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Reserpine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Reserpine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Reserpine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Reserpine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Reserpine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Reserpine in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Reserpine in the drug label.

Condition1
  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Reserpine in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Reserpine in the drug label.

Pharmacology

Template:Px
Reserpine
Systematic (IUPAC) name
Methyl (3β,16β,17α,18β,20α)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate
Identifiers
CAS number 50-55-5
ATC code C02AA02
PubChem 5770
DrugBank DB00206
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 608.68 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 50%
Metabolism gut/liver
Half life phase 1 = 4.5h,
phase 2 = 271h,
average = 33h
Excretion 62% feces / 8% urine
Therapeutic considerations
Licence data

US

Pregnancy cat.

C Risk cannot be ruled out, US

Legal status

Rx-only (some countries banned/discontinued)

Routes oral

Mechanism of Action

Structure

  • Reserpine, USP is an antihypertensive, available as 0.1 mg and 0.25 mg tablets for oral administration. Its chemical name is methyl 18β-hydroxy-11,17 α-dimethoxy-3β, 20α-yohimban-16β-carboxylate 3,4,5-trimethoxybenzoate (ester) and its structural formula is:

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Reserpine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Reserpine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Reserpine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Reserpine in the drug label.

Condition1
  • Description

How Supplied

Storage

There is limited information regarding Reserpine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Reserpine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Reserpine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Reserpine in the drug label.

Precautions with Alcohol

  • Alcohol-Reserpine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • Resa®

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "RESERPINE tablet".
  2. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Reserpine
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Reserpine
 |Label Name=No image.jpg

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Reserpine&oldid=988499"